FDA Hosts Workshop to Improve Community Access to Life-Saving Epinephrine
Published Date: 11/24/2025
Notice
Summary
The FDA is hosting a workshop on December 16, 2025, to talk about making epinephrine easier to get for people who might have severe allergic reactions (anaphylaxis). This effort aims to save lives by getting epinephrine into more hands, especially in community places. Everyone can join online or in person and share their thoughts by January 16, 2026, helping shape future access and safety improvements.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Many at-risk patients lack or avoid epinephrine
Anaphylaxis can progress within 15 to 30 minutes and epinephrine is the only effective first-line treatment. The document says up to 5 percent lifetime prevalence in the U.S. and about 200 deaths annually, and it notes patients prescribed epinephrine may not have it available during an event or may choose not to use it because of knowledge gaps, fear, stigma, or incorrect use.
Community sites often lack epinephrine policies
Schools, workplaces, restaurants, sports facilities, transportation vehicles, and public venues may lack policies for epinephrine storage, staff training, and emergency administration. That institutional lack of preparedness can reduce access to epinephrine where anaphylaxis commonly happens.
State liability rules discourage stocking epinephrine
State laws vary regarding Good Samaritan protections for lay administration of epinephrine, and these liability concerns can discourage institutions from maintaining emergency epinephrine supplies.
Cost of epinephrine limits community availability
The document identifies economic obstacles from the cost of epinephrine products as a barrier to having community‑use epinephrine available in public settings, which can limit access during emergencies.
Rural disparities reduce timely epinephrine access
The document notes geographic disparities, especially in rural communities where pharmacies may be spread out and emergency medical services can have longer response times, which can limit timely access to epinephrine.
Prescription and provider authorization create access hurdles
The notice identifies procedural barriers such as obtaining healthcare provider authorization and maintaining a current prescription for epinephrine as factors that can limit access to this life‑saving medication.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-20657, Carroll County Energy LLC; Notice of Institution of Section 206 Proceeding And Refund Effective Date
The Federal Energy Regulatory Commission is checking if Carroll County Energy LLC’s rates are fair or not. If they find the rates unfair, refunds could start from November 24, 2025. Anyone interested has 21 days to speak up and get involved in the process.
Next: 2025-20659, Agency Information Collection Activities; Proposed eCollection eComments Requested; DEA Voluntary Wellness Program Healthcare Provider Clearance
The Drug Enforcement Administration (DEA) wants your feedback on a new form for their Voluntary Wellness Program aimed at healthcare providers. They’re asking for comments by December 24, 2025, to make sure the form is easy to use and not too time-consuming. This helps the DEA improve the program without costing extra money or hassle for those involved.